Related Experiment Video

Updated: Mar 14, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy

Nadeem Riaz1,2,3, Jonathan J Havel1, Sviatoslav M Kendall1

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Nature Genetics
|September 27, 2016
PubMed

Insights

Somatic mutations in SERPINB3 and SERPINB4 genes are linked to patient survival following anti-CTLA4 immunotherapy for melanoma. These findings may help personalize cancer treatment strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint blockade, including anti-CTLA4 therapy, offers promising anticancer effects.
  • Understanding the factors influencing patient response to immunotherapy remains crucial for treatment optimization.

Purpose of the Study:

  • To investigate the association between somatic mutations in SERPINB3 and SERPINB4 genes and patient survival outcomes after anti-CTLA4 immunotherapy.
  • To explore the role of serpin homologs in the context of melanoma and autoimmunity.

Main Methods:

  • Analysis of somatic mutations in SERPINB3 and SERPINB4 genes.
  • Correlation of mutation status with survival data in two independent patient cohorts with melanoma (n=174).

Main Results:

  • Somatic mutations in SERPINB3 and SERPINB4 were found to be associated with survival in patients undergoing anti-CTLA4 immunotherapy.
  • Serpins, identified as homologs of the ovalbumin antigen, were noted for their association with autoimmune conditions.

Conclusions:

  • Somatic mutations in SERPINB3 and SERPINB4 may serve as predictive biomarkers for anti-CTLA4 immunotherapy response in melanoma patients.
  • The study highlights potential avenues for personalizing immunotherapy strategies based on genetic profiles.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K